DELAVIRDINE

US Previously Marketed

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H28N6O3S
Molecular Weight	456.561
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)NC1=CC=CN=C1N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(NS(C)(=O)=O)=C4

InChI

InChIKey=WHBIGIKBNXZKFE-UHFFFAOYSA-N

InChI=1S/C22H28N6O3S/c1-15(2)24-19-5-4-8-23-21(19)27-9-11-28(12-10-27)22(29)20-14-16-13-17(26-32(3,30)31)6-7-18(16)25-20/h4-8,13-15,24-26H,9-12H2,1-3H3

HIDE SMILES / InChI

Molecular Formula	C22H28N6O3S
Molecular Weight	456.561
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf | https://www.drugs.com/ppa/delavirdine.html

Delavirdine is a nonnucleoside reverse transcriptase inhibitor (NNRTI). Delavirdine binds directly to reverse transcriptase (RT) and blocks RNA-dependent and DNA-dependent DNA polymerase activities. Delavirdine does not compete with template:primer or deoxynucleoside triphosphates. HIV-2 RT and human cellular DNA polymerases alfa, gamma, or delta are not inhibited by delavirdine. In addition, HIV-1 group O, a group of highly divergent strains that are uncommon in North America, may not be inhibited by delavirdine. Delavirdine is marketed under the trade name Rescriptor, indicated for the treatment of HIV-1 infection in combination with at least 2 other active antiretroviral agents when therapy is warranted. .

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Human immunodeficiency virus type 1 reverse transcriptase 70 Target ID: CHEMBL247 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/26162497 \| https://www.ncbi.nlm.nih.gov/pubmed/10514285	Inhibitor 8504		21.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
HIV-1 infection 156 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf	Primary		Approved 8583	RESCRIPTOR Approved Use RESCRIPTOR Tablets are indicated for the treatment of HIV-1 infection in combination with at least 2 other active antiretroviral agents when therapy is warranted. The following should be considered before initiating therapy with RESCRIPTOR in treatment-naive patients. There are insufficient data directly comparing antiretroviral regimens containing RESCRIPTOR with currently preferred 3-drug regimens for initial treatment of HIV. In studies comparing regimens consisting of 2 nucleoside reverse transcriptase inhibitors (NRTIs) (currently considered suboptimal) to RESCRIPTOR plus 2 NRTIs, the proportion of patients receiving the regimen containing RESCRIPTOR who achieved and sustained an HIV-1 RNA level <400 copies/mL over 1 year of therapy was relatively low (see DESCRIPTION OF CLINICAL STUDIES). Resistant virus emerges rapidly when RESCRIPTOR is administered as monotherapy. Therefore, RESCRIPTOR should always be administered in combination with other antiretroviral agents. Launch Date 1997

C_max

Value	Dose	Analyte	Population
12.6 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
18.8 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	300 mg 3 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
26.6 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	400 mg 3 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
2.18 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	N-DESISOPROPYL DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
2.88 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	300 mg 3 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	N-DESISOPROPYL DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
3.23 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	400 mg 3 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	N-DESISOPROPYL DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
35 μM DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20705s03lbl.pdf	400 mg 3 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
180 μM × h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20705s03lbl.pdf	400 mg 3 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
2.59 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
3.33 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	300 mg 3 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
4.12 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	400 mg 3 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
4.71 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	N-DESISOPROPYL DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
6.18 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	300 mg 3 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	N-DESISOPROPYL DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
7.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	400 mg 3 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	N-DESISOPROPYL DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
5.8 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20705s03lbl.pdf	400 mg 3 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Analyte	Population
2.3% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
2.3% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	300 mg 3 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
2.3% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	400 mg 3 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
2% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20705s03lbl.pdf	400 mg 3 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
400 mg 3 times / day steady, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10348755	unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/10348755	Disc. AE: Rash, Oral lesion... Other AEs: Fever, Thrombocytopenia... AEs leading to discontinuation/dose reduction: Rash (grade 3-4, 36%) Oral lesion (1 patient) Function liver abnormal (2 patients) Headache (grade 4, 1 patient) Other AEs: Fever (grade 3, 1 patient) Thrombocytopenia (1 patient) Nausea (1 patient) Fatigue (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/10348755
400 mg 3 times / day multiple, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: multiple Dose: 400 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf	Disc. AE: Rash... AEs leading to discontinuation/dose reduction: Rash (3.2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf

AEs

AE	Significance	Dose	Population
Fatigue	1 patient	400 mg 3 times / day steady, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10348755	unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/10348755
Nausea	1 patient	400 mg 3 times / day steady, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10348755	unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/10348755
Thrombocytopenia	1 patient	400 mg 3 times / day steady, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10348755	unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/10348755
Oral lesion	1 patient Disc. AE	400 mg 3 times / day steady, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10348755	unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/10348755
Function liver abnormal	2 patients Disc. AE	400 mg 3 times / day steady, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10348755	unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/10348755
Fever	grade 3, 1 patient	400 mg 3 times / day steady, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10348755	unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/10348755
Rash	grade 3-4, 36% Disc. AE	400 mg 3 times / day steady, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10348755	unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/10348755
Headache	grade 4, 1 patient Disc. AE	400 mg 3 times / day steady, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10348755	unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/10348755
Rash	3.2% Disc. AE	400 mg 3 times / day multiple, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: multiple Dose: 400 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
	inhibitor 2438	substrate 1388 inhibitor 2507

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP3A 227 CYP2C19 2057 P-gp 1741 MRP1 116 MRP2 499 MRP3 246 CYP1A2 2153	CYP3A 220 P-gp 2052	P-gp 301

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A2 2333	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/11225565/	negligible
MRP1 232	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/17172311/	yes [Inhibition 16.7 uM]
MRP2 625	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/17172311/	yes [Inhibition 16.7 uM]
MRP3 326	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/17172311/	yes [Inhibition 16.7 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf#page=3;https://pubmed.ncbi.nlm.nih.gov/11124228/ Page: 3.0	yes [Ki 12.8 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf#page=3;https://pubmed.ncbi.nlm.nih.gov/11124228/ Page: 3.0	yes [Ki 2.6 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf#page=3; https://pubmed.ncbi.nlm.nih.gov/11124228/ Page: 3.0	yes [Ki 24 uM]
CYP3A 317	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf#page=3;https://pubmed.ncbi.nlm.nih.gov/15544435/ Page: 3.0	yes [Ki 9.5 uM]	yes (co-administration study) Comment: coadministration of amprenavir with delavirdine resulted in an approximately 4-fold increase in amprenavir AUC to infinity (AUC∞) and a 6-fold increase in amprenavir Cmin Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf#page=3;https://pubmed.ncbi.nlm.nih.gov/15544435/ Page: 3.0
P-gp 1932	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/12180537/	yes
P-gp 1932	inhibitor 4027 Sources: https://aac.asm.org/content/48/4/1073	yes

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP2D6 1388	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf#page=3 Page: 3.0	likely
P-gp 2052	substrate 4014 Sources: https://aac.asm.org/content/48/4/1073	no
CYP3A 220	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf#page=3 Page: 3.0	yes	yes (co-administration study) Comment: Coadministration of RESCRIPTOR and drugs that induce CYP3A, such as rifampin, may decrease delavirdine plasma concentrations and reduce its therapeutic effect. With rifampin: 97% decrease in AUC Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf#page=3 Page: 3.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:119573	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:119573
ChemicalBook	CB8292151	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB8292151
eMolecules	1989427	https://www.emolecules.com/cgi-bin/more?vid=1989427
MolPort	MolPort-003-846-188	https://www.molport.com/shop/molecule-link/MolPort-003-846-188
ZINC	ZINC000018516586	http://zinc15.docking.org/substances/ZINC000018516586

PubMed

Title	Date	PubMed
Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants.	2004-05-06	15115397
Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.	2004-04-01	15031785
Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.	2004-02-26	14971897
Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.	2004-02	15040537
Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trials.	2004-01-31	14742351
3-iodo-4-phenoxypyridinones (IOPY's), a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.	2003-12-15	14643315
Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies.	2003-12-05	14685057
Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia.	2003-11-17	14612892
Identification and prediction of promiscuous aggregating inhibitors among known drugs.	2003-10-09	14521410
Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.	2003-10	14640386
Pfizer announces free drug program.	2003-09	14596253
Drug resistance profiles of recombinant reverse transcriptases from human immunodeficiency virus type 1 subtypes A/E, B, and C.	2003-09	14585205
Use of HIV-1 reverse transcriptase recovered from human plasma for phenotypic drug susceptibility testing.	2003-07-04	12824784
Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1.	2003-06-13	12799573
Protease inhibitor-sparing regimens: new evidence strengthens position.	2003-06-01	12946062
Comparison of nine resistance interpretation systems for HIV-1 genotyping.	2003-06	12924541
Toxicity of non-nucleoside analogue reverse transcriptase inhibitors.	2003-05	12800070
Pharmacia pilots patent share for HIV drug.	2003-04	12680360
Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography.	2003-02-05	12505781
Delavirdine malabsorption in HIV-infected subjects with spontaneous gastric hypoacidity.	2003-02	12616670
A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors.	2003-01-03	12478089
Pharmacokinetic interaction between amprenavir and delavirdine after multiple-dose administration in healthy volunteers.	2003-01	12534646
Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication.	2003-01	12502865
Synthesis of novel N-1 (allyloxymethyl) analogues of 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine) with improved activity against HIV-1 and its mutants.	2002-12-19	12477355
Genotypic and phenotypic resistance patterns in early-stage HIV-1-infected patients failing initial therapy with stavudine, didanosine and nevirapine.	2002-12	12553483
Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir.	2002-12	12496743
Structural requirements for potent anti-human immunodeficiency virus (HIV) and sperm-immobilizing activities of cyclohexenyl thiourea and urea non-nucleoside inhibitors of HIV-1 reverse transcriptase.	2002-12	12444075
New anti-HIV agents and targets.	2002-11	12369088
Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance.	2002-11	12367719
Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates.	2002-10-18	12370521
Effect of delavirdine on plasma lipids and lipoproteins in patients receiving antiretroviral therapy.	2002-09-06	12218397
Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359.	2002-09-01	12195349
New developments in anti-HIV chemotherapy.	2002-07-18	12084468
Simple and rapid quantification of the non-nucleoside reverse transcriptase inhibitors nevirapine, delavirdine, and efavirenz in human blood plasma using high-performance liquid chromatography with ultraviolet absorbance detection.	2002-07-05	12052725
Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture.	2002-07	12180537
Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT.	2002-07	12069959
Delavirdine in rescue regimens.	2002-06-18	12064317
Rifampin and rifabutin drug interactions: an update.	2002-05-13	11996607
Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine.	2002-04-15	11959068
Synthesis, biological evaluation, and binding mode of novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles targeted at the HIV-1 reverse transcriptase.	2002-04-11	11931611
Determination of delavirdine in very small volumes of plasma by high-performance liquid chromatography with fluorescence detection.	2002-04-05	11996495
Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors.	2002-04-01	11917237
Delavirdine increases drug exposure of ritonavir-boosted protease inhibitors.	2002-03-29	11964540
Nelfinavir urinary stones.	2002-03	11832739
Can delavirdine substitute for ritonavir?	2002-01-25	11794866
Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection.	2002	12405866
Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives.	2002	11945162
Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapy.	2001-12-14	11742431
[Therapeutic aspects of HIV/AIDS infected patients and evaluation of therapeutic protocols].	2001-12	12113183
Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors.	2001	11735608

Patents

Sample Use Guides

In Vivo Use Guide

HIV-1 infection (part of combination): Oral: 400 mg 3 times/day

Route of Administration: Oral

In Vitro Use Guide

In vitro anti-HIV-1 activity of delavirdine was assessed by infecting cell lines of lymphoblastic and monocytic origin and peripheral blood lymphocytes with laboratory and clinical isolates of HIV-1. IC50 and IC90 values (50% and 90% inhibitory concentrations) for laboratory isolates (n = 5) ranged from 0.005 to 0.030 uM and 0.04 to 0.10 uM, respectively. Mean IC50 of clinical isolates (n = 74) was 0.038 uM (range: 0.001 to 40 0.69 uM); 73 of 74 clinical isolates had an IC50

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:09:12 GMT 2025` Edited by `admin` on `Mon Mar 31 18:09:12 GMT 2025`
Record UNII	DOL5F9JD3E
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DELAVIRDINE

Official Name

English

DELAVIRDINE [MI]

Preferred Name

English

DELAVIRDINE [VANDF]

Common Name

English

Delavirdine [WHO-DD]

Common Name

English

PIPERAZINE, 1-(3-((1-METHYLETHYL)AMINO)-2-PYRIDINYL)-4-((5-((METHYLSULFONYL)AMINO)-1H-INDOL-2-YL)CARBONYL)-

Systematic Name

English

delavirdine [INN]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000009948